4.8 Article

Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 10, 期 468, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aat6420

关键词

-

资金

  1. Comision Nacional de Investigacion Cientifica y Tecnologica, Gobierno de Chile (CONICYT) [FONDECYT 11140561]
  2. CONICYT FONDEF/I Concurso IDeA en Dos Etapas [ID14I10084]
  3. FONDEF [ID14I20084]
  4. CONICYT/FONDEQUIP [EQM150134, EQM150061]
  5. MECESUP UCO [1408-PM]
  6. Universidad de Concepcion [VRID 214.036.042-1]
  7. Ichor Biologics - Intramural Research Program of the National Institute of Allergy and Infectious Diseases

向作者/读者索取更多资源

Andes hantavirus (ANDV) is an etiologic agent of hantavirus cardiopulmonary syndrome (HCPS), a severe disease characterized by fever, headache, and gastrointestinal symptoms that may progress to hypotension, pulmonary failure, and cardiac shock that results in a 25 to 40% case-fatality rate. Currently, there is no specific treatment or vaccine; however, several studies have shown that the generation of neutralizing antibody (Ab) responses strongly correlates with survival from HCPS in humans. In this study, we screened 27 ANDV convalescent HCPS patient sera for their capacity to bind and neutralize ANDV in vitro. One patient who showed high neutralizing titer was selected to isolate ANDV-glycoprotein (GP) Abs. ANDV-GP-specific memory B cells were single cell sorted, and recombinant immunoglobulin G antibodies were cloned and produced. Two monoclonal Abs (mAbs), JL16 and MIB22, potently recognized ANDV-GPs and neutralized ANDV. We examined the post-exposure efficacy of these two mAbs as a monotherapy or in combination therapy in a Syrian hamster model of ANDV-induced HCPS, and both mAbs protected 100% of animals from a lethal challenge dose. These data suggest that monotherapy with mAb JL16 or MIB22, or a cocktail of both, could be an effective post-exposure treatment for patients infected with ANDV-induced HCPS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据